Caris Life Sciences, Inc.
Financials
Valuation Metrics
Caris Life Sciences, Inc.'s Market Cap is $8.47B. At end of 2025 it was $45.11B. Ranked #1007 of 3,121 in US market (top 32%), #324 of 1,463 on NASDAQ (top 22%), #52 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 20%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $8.47B | US#1,007/3,121 Sec#52/266 |
| Revenue | $990M | US#1,896/3,121 Sec#52/266 |
| Net Income | $105M | US#1,603/3,121 Sec#52/266 |
| Total Assets | $1.23B | US#2,382/3,121 Sec#84/266 |
| Net Assets | $592M | US#2,117/3,121 Sec#98/266 |
| Employees | 1,846 | US#1,730/3,121 Sec#43/266 |
| Value | ||
| P/E | 80.61x | US#2,066/3,121 Sec#62/266 |
| P/B | 14.32x | US#2,731/3,121 Sec#207/266 |
| P/S | 8.56x | US#2,647/3,121 Sec#107/266 |
| EV/EBITDA | 47.69x | US#2,362/3,121 Sec#72/266 |
| FCF Yield | 1.46% | US#2,128/3,121 Sec#73/266 |
| Profitability | ||
| ROE | 17.77% | US#711/3,121 Sec#36/266 |
| ROA | 8.55% | US#598/3,121 Sec#40/266 |
| Op. Margin | 15.49% | US#1,179/3,121 Sec#48/266 |
| Revenue Growth | 104.87% | US#92/3,121 Sec#34/266 |
| Financial Health | ||
| Debt Ratio | 107.80% | US#1,173/3,121 Sec#170/266 |
| Total Debt | $452M | US#1,920/3,121 Sec#65/266 |
| FCF | $124M | US#1,648/3,121 Sec#58/266 |
| Cash | $691M | US#874/3,121 Sec#39/266 |
| Current Ratio | 5.53x | US#427/3,121 Sec#133/266 |
| Net Debt/EBITDA | -1.38x | US#244/3,121 Sec#18/266 |
| Performance | ||
| 1Y Return | -10.32% | US#2,052/3,121 Sec#197/266 |
| 1M Return | 31.72% | US#14/3,121 Sec#5/266 |
| From 52W High | -10.91% | US#656/3,121 Sec#48/266 |
| 1Y MDD | -55.84% | US#2,667/3,121 Sec#201/266 |
| Trading | ||
| Volume | 9,812,550 shares | US#213/3,121 Sec#15/266 |
| Trading Value | $297M | US#410/3,121 Sec#22/266 |
| Per Share | ||
| EPS | $0.37 | US#1,941/3,121 Sec#64/266 |
| BPS | $2.09 | US#2,569/3,121 Sec#180/266 |
Company Info
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.